Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Jain, Lokesh ^a,b   Sissung, Tristan M ^a   Danesi, Romano ^c   Kohn, Elise C ^a   Dahut, William L ^a   Kummar, Shivaani ^a   Venzon, David ^a   Liewehr, David ^a   English, Bevin C ^a   Baum, Caitlin E ^a   Yarchoan, Robert ^a   Giaccone, Giuseppe ^a   Venitz, Jürgen ^b   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DOCETAXEL; PROTEINASE INHIBITOR; SORAFENIB; THALIDOMIDE; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DNA; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE;

ALLELE; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FATIGUE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; KAPOSI SARCOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME; FEMALE; GENETICS; HAND DISEASE; MALE; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; SKIN DISEASE; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DNA, NEOPLASM; FEMALE; FOOT DERMATOSES; GENOTYPE; HAND DERMATOSES; HUMANS; HYPERTENSION; MALE; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955240423     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-95     Document Type: Article

References (23)

1. Angiogenesis and ovarian cancer. C Gomez-Raposo M Mendiola J Barriuso E Casado D Hardisson A Redondo, Clin Transl Oncol 2009 11 564 571 10.1007/s12094-009-0406-y 19775995
2. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. AW Griffioen G Molema, Pharmacol Rev 2000 52 237 268 10835101
3. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. BI Rini, Cancer 2009 115 2306 2312 10.1002/cncr.24227 19402073
4. Intricacies of bevacizumab-induced toxicities and their management. SM Gressett SR Shah, Ann Pharmacother 2009 43 490 501 10.1345/aph.1L426 19261963
5. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. C Porta C Paglino I Imarisio L Bonomi, Clin Exp Med 2007 7 127 134 10.1007/s10238-007-0145-8 18188524
6. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. V Launay-Vacher G Deray, Anticancer Drugs 2009 20 81 82 10.1097/CAD. 0b013e3283161012 19343005
7. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. NS Azad JB Aragon-Ching WL Dahut M Gutierrez WD Figg L Jain SM Steinberg ML Turner EC Kohn HH Kong, Clin Cancer Res 2009 15 1411 1416 10.1158/1078-0432.CCR-08-1141 19228742
8. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. G Fuh B Li C Crowley B Cunningham JA Wells, J Biol Chem 1998 273 11197 11204 10.1074/jbc.273.18.11197 9556609
9. Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. Q Tao MV Backer JM Backer BI Terman, J Biol Chem 2001 276 21916 21923 10.1074/jbc.M100763200 11399777
10. Polymorphisms of KDR gene are associated with coronary heart disease. Y Wang Y Zheng W Zhang H Yu K Lou Y Zhang Q Qin B Zhao Y Yang R Hui, J Am Coll Cardiol 2007 50 760 767 10.1016/j.jacc.2007.04.074 17707181
11. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. JB Aragon-Ching L Jain JL Gulley PM Arlen JJ Wright SM Steinberg D Draper J Venitz E Jones CC Chen,, et al. BJU Int 2009 103 1636 1640 10.1111/j.1464-410X.2008.08327.x 19154507
12. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). JG YM Ning P Arlen L Latham A Retter J Wright H Parnes P Pinto WD Figg WL Dahut, American Society of Clinical Oncology (ASCO) 2007
13. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). SK M Gutierrez D Allen B Turkbey P Choyke JJ Wright C Kurkjian G Giaccone JH Doroshow AJ Murgo, American Society of Clinical Oncology (ASCO) 2008
14. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. NS Azad EM Posadas VE Kwitkowski SM Steinberg L Jain CM Annunziata L Minasian G Sarosy HL Kotz A Premkumar,, et al. J Clin Oncol 2008 26 3709 3714 10.1200/JCO.2007.10.8332 18669456
15. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. TM Sissung CE Baum J Deeken DK Price J Aragon-Ching SM Steinberg W Dahut A Sparreboom WD Figg, Clin Cancer Res 2008 14 4543 4549 10.1158/1078-0432.CCR-07- 4230 18628469
16. J D Kalbfleisch R L Prentice, The Statistical Analysis of Failure Time Data New York: John Wiley and Sons 2 1980
17. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? D Strumberg A Awada H Hirte JW Clark S Seeber P Piccart E Hofstra D Voliotis O Christensen A Brueckner B Schwartz, Eur J Cancer 2006 42 548 556 10.1016/j.ejca.2005.11.014 16426838
18. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. M Scartozzi E Galizia S Chiorrini R Giampieri R Berardi C Pierantoni S Cascinu, Ann Oncol 2009 20 227 230 10.1093/annonc/mdn637 18842611
19. Discovery of a novel Raf kinase inhibitor. JF Lyons S Wilhelm B Hibner G Bollag, Endocr Relat Cancer 2001 8 219 225 10.1677/erc.0.0080219 11566613
20. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. SM Wilhelm C Carter L Tang D Wilkie A McNabola H Rong C Chen X Zhang P Vincent M McHugh,, et al. Cancer Res 2004 64 7099 7109 10.1158/0008-5472.CAN-04-1443 15466206
21. Skin toxicities of targeted therapies. S Segaert G Chiritescu L Lemmens K Dumon E Van Cutsem S Tejpar, Eur J Cancer 2009 45 Suppl 1 295 308 10.1016/S0959-8049(09)70044-9 19775626
22. Rash correlates with tumour response after cetuximab. E Susman, Lancet Oncol 2004 5 647 10.1016/S1470-2045(04)01627-4 15536688
23. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. BP Schneider M Wang M Radovich GW Sledge S Badve A Thor DA Flockhart B Hancock N Davidson J Gralow,, et al. J Clin Oncol 2008 26 4672 4678 10.1200/JCO.2008.16.1612 18824714